<img src="https://dominatethemarkets.com/wp-content/uploads/2023/05/dominate_the_markets.png" class="logo-image" alt="Dominate The Markets" data-at2x="https://dominatethemarkets.com/wp-content/uploads/2023/05/dominate_the_markets.png" />

<img width="740" height="357" src="https://dominatethemarkets.com/wp-content/uploads/2023/05/56612307-m-normal-none-3OVgax-740x357.jpeg" class="attachment-motive-alt-slider size-motive-alt-slider wp-post-image" alt="" decoding="async" title="Cramer dubs Lilly’s Alzheimer’s drug a ‘holy grail’ after today’s data" srcset="https://dominatethemarkets.com/wp-content/uploads/2023/05/56612307-m-normal-none-3OVgax-740x357.jpeg 740w, https://dominatethemarkets.com/wp-content/uploads/2023/05/56612307-m-normal-none-3OVgax-352x169.jpeg 352w" sizes="(max-width: 740px) 100vw, 740px" />

Cramer dubs Lilly’s Alzheimer’s drug a ‘holy grail’ after today’s data

0

By on May 3, 2023 Stock Top News

[#item_full_content]

<img alt='' src='https://secure.gravatar.com/avatar/?s=78&d=mm&r=g' srcset='https://secure.gravatar.com/avatar/?s=156&d=mm&r=g 2x' class='avatar avatar-78 photo avatar-default' height='78' width='78' decoding='async'/>

Previous ArticleLloyds stock outlook after a 47% increase in Q1 profit

Next Article Fed raises rates by 25 bps: Citi sees 10% downside in S&P 500